Pallomino Therapeutics

A well-characterized human enzyme, when disrupted, causes a rare genetic disease. Restoring its function may also address a much more common adult condition. We're building the molecules to do both.

Pallomino Therapeutics is an early-stage drug discovery company based in Toronto, developing small molecule therapies against a human enzyme target with clear genetic and mechanistic links to disease.


A validated mechanism, an unaddressed target

We work on human enzymes that are difficult to drug with conventional methods but have clear genetic and mechanistic links to disease. Our first program targets an enzyme where loss-of-function mutations cause a rare, early-onset condition, and where the same enzyme's activity may also be relevant to a much larger adult population.No clinically approved small molecule therapy exists for this target today.


Early discovery, right now

We are at the target-validation and early screening stage. No development candidate has been confirmed yet.


A platform, not a single shot

Our approach uses a live-cell phenotypic screening platform, developed at the University of Toronto, designed to detect small molecules that restore normal function of a target enzyme in a cellular context, something conventional biochemical assays cannot do at scale. The platform is not limited to a single target or a single disease area.

The team.

Dr. Peter Roy, Co-Founder and Chief Scientific Officer.

Professor, Department of Molecular Genetics, University of Toronto. Over 20 years of experience in drug screens and model organism biology.

Kate Rootman, Co-Founder and CEO.

Leads strategy, business development, IP, and investor relationships. Background in innovation strategy and early-stage commercialization.


We are building something worth watching.

If you would like to learn more, we would be glad to talk. Email us at [email protected]

Pallomino Therapeutics · Toronto, Canada Non-confidential overview · © 2026